Cannabinoid bioscience has come a long way. New York-based Axim Biotech is at the forefront, developing – among many other, related products – a multi-layered, slow-release cannabinoid chewing gum. Not for the candy stand, MedChewRx® is seeking FDA and EMA approval for the treatment of pain and spasticity associated with multiple sclerosis. Characteristically, QPS is in charge of managing the entire project, including clinical trials.
Watch the video on Axim’s approach to cannabinoids research.